Molecular characterization of ferroptosis in soft tissue sarcoma constructs a prognostic and immunotherapeutic signature through experimental and bioinformatics analyses.
ferroptosis
immunotherapy
nomogram
soft tissue sarcoma
survival analysis
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
20 10 2023
20 10 2023
Historique:
received:
12
06
2023
accepted:
02
10
2023
medline:
7
11
2023
pubmed:
24
10
2023
entrez:
24
10
2023
Statut:
ppublish
Résumé
Ferroptosis regulators have been found to affect tumor progression. However, studies focusing on ferroptosis and soft tissue sarcoma (STS) are rare. Somatic mutation, copy number variation, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis, consensus clustering, differentially expressed genes analysis (DEGs), principal component analysis (PCA) and gene set enrichment analysis (GSEA) were used to identify and explore different ferroptosis modifications in STS. A nomogram was constructed to predict the prognosis of STS. Moreover, three immunotherapy datasets were used to assess the Fescore. Western blotting, siRNA transfection, EdU assay and reactive oxygen species (ROS) measurement were performed. 16 prognostic ferroptosis regulators were screened and significant differences were observed in somatic mutation, copy number variation (CNV) and RT-qPCR among these ferroptosis regulators. 2 different ferroptosis modification patterns were found (Fe cluster A and B). Fe cluster A with higher Fescore was correlated with p53 pathway and had better prognosis of STS (
Identifiants
pubmed: 37874682
pii: 205133
doi: 10.18632/aging.205133
pmc: PMC10637810
doi:
Substances chimiques
Reactive Oxygen Species
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11412-11447Références
Cell. 2021 Aug 19;184(17):4512-4530.e22
pubmed: 34343496
Cell. 1997 Feb 7;88(3):323-31
pubmed: 9039259
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Toxicol Lett. 2016 Sep 6;258:227-236
pubmed: 27392435
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Front Physiol. 2018 Jun 15;9:699
pubmed: 29962955
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Biol Chem. 2022 Mar;298(3):101703
pubmed: 35148992
BMC Plant Biol. 2014 Jun 17;14:169
pubmed: 24939556
J Natl Cancer Inst. 2006 Feb 15;98(4):262-72
pubmed: 16478745
Lancet Oncol. 2017 Nov;18(11):1493-1501
pubmed: 28988646
Int Immunopharmacol. 2014 May;20(1):117-23
pubmed: 24606770
Bioinformatics. 2010 Sep 15;26(18):2347-8
pubmed: 20656902
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
Cancer Lett. 2021 Dec 28;523:10-28
pubmed: 34597712
Cancers (Basel). 2021 Apr 29;13(9):
pubmed: 33946962
Surgeon. 2005 Jun;3(3):216-23
pubmed: 16076008
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
React Oxyg Species (Apex). 2016;2(5):361-370
pubmed: 29721549
Immunol Lett. 2017 Apr;184:7-14
pubmed: 28223102
Pharmacogn Mag. 2017 Jul-Sep;13(51):523-527
pubmed: 28839383
Cell Mol Biol Lett. 2021 Jun 7;26(1):26
pubmed: 34098867
NPJ Precis Oncol. 2021 Nov 19;5(1):97
pubmed: 34799669
Microcirculation. 2002 Apr;9(2):133-45
pubmed: 11932780
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Genome Res. 2009 Sep;19(9):1639-45
pubmed: 19541911
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3070-4
pubmed: 1348364
Nat Commun. 2021 Aug 24;12(1):5103
pubmed: 34429409
Cancer Lett. 2021 Dec 1;522:1-13
pubmed: 34520818
EMBO Rep. 2021 Oct 5;22(10):e52537
pubmed: 34459531
ISRN Oncol. 2011;2011:168712
pubmed: 22084725
Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):941-9
pubmed: 10571201
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33757986
Clin Cancer Res. 2022 Aug 15;28(16):3573-3589
pubmed: 35421237
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
BMC Cancer. 2016 Oct 22;16(1):821
pubmed: 27770790
Cancers (Basel). 2023 Jan 15;15(2):
pubmed: 36672483
Cancer Sci. 2017 Nov;108(11):2187-2194
pubmed: 28837253
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
J Clin Oncol. 2013 Feb 10;31(5):608-15
pubmed: 23319690
Nat Commun. 2013;4:2612
pubmed: 24113773
Int J Biol Macromol. 2020 Oct 15;161:1230-1239
pubmed: 32544581
J Exp Clin Cancer Res. 2018 Aug 29;37(1):207
pubmed: 30157903
Int J Biol Sci. 2020 Jul 6;16(13):2430-2441
pubmed: 32760210
Front Bioeng Biotechnol. 2022 Apr 19;10:846812
pubmed: 35519620
Biometrics. 2000 Jun;56(2):337-44
pubmed: 10877287
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970
Int J Cancer. 2020 Jan 15;146(2):510-520
pubmed: 31173656
Science. 2006 Sep 29;313(5795):1929-35
pubmed: 17008526
Eur J Surg Oncol. 2022 Jul;48(7):1527-1535
pubmed: 35221159
Biochem Biophys Res Commun. 2021 Dec 10;582:77-85
pubmed: 34695754